《半日速報》恆指半日收報23,209點 跌14點; 恆生科技指數半日收報5,563點 跌55點 吉利跌逾4%
恆指半日收23,209點,跌14點或0.1%。恆生科技指數報5,563點,跌55點或1.0%。國指跌26點或0.3%,報8,175點。
活躍重磅股表現:
騰訊(00700.HK) 收447元,下跌2.9%;
美團(03690.HK) 收221元,下跌2.2%;
平安(02318.HK) 收57.15元,上升1.8%;
建行(00939.HK) 收5.41元,上升0.9%;
阿裏巴巴(09988.HK) 收113.5元,上升0.4%;
友邦(01299.HK) 收78.95元,上升0.2%;
港交所(00388.HK) 收453.8元,上升0.2%;
異動恆指及國指成份股:
吉利(00175.HK) 收20.9元,下跌4.8%;
融創中國(01918.HK) 收11.68元,上升4.5%;
恆隆地產(00101.HK) 收16.34元,上升4.1%;
信達生物(01801.HK) 收47.4元,下跌4%;
長實集團(01113.HK) 收49.65元,上升4%;
快手-W(01024.HK) 收72.9元,下跌3.5%;
信義玻璃(00868.HK) 收19.6元,上升3.5%;
阿裏健康(00241.HK) 收6.35元,下跌3.1%;
銀娛(00027.HK) 收39.8元,下跌3%;
異動綜合中小型股:
開拓藥業-B(09939.HK) 收14.68元,下跌67.5%;
中國信達(01359.HK) 收1.48元,上升13.8%;
藥明巨諾-B(02126.HK) 收13.54元,下跌13.2%;
中國中藥(00570.HK) 收4.61元,上升12.4%;
基石藥業-B(02616.HK) 收7.48元,下跌11.5%;
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.